Navigation Links
Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimer's Disease
Date:10/5/2010

BROOMFIELD, Colo., Oct. 5 /PRNewswire/ -- Accera, Inc., a medical research and development company delivering breakthrough therapies for serious diseases such as Alzheimer's disease (AD), announced today that Thomas Werner, Ph.D., has been appointed President and CEO.  Concurrently with Dr. Werner's appointment, the U.S. Food and Drug Administration (FDA) has accepted Accera's Investigational New Drug (IND) application to conduct a phase 2-3 clinical study in patients with mild-to-moderate AD with its product AC-1204.  

Dr. Werner was elected to Accera's board of directors in March 2009.  Prior to his election, he was the managing director and senior vice president of GlaxoSmithKline (GSK) in Germany and had served as CEO of the GSK Foundation until early 2009.  Dr. Werner was instrumental in the development of successful growth strategies for the German subsidiaries of GSK and Bristol-Myers Squibb.  Under his leadership, the ACE inhibitor Captopril became the largest selling pharmaceutical product in Germany, and the asthma drug Viani™ grew to become one of the leading pharmaceutical products in Germany.

Dr. Werner cofounded the Genetic Research Center, a joint venture with the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University, both in Munich.  Dr. Werner earned his Ph.D. in chemistry at the University of Gottingen in Germany.

"We are delighted to appoint Dr. Werner as Accera's president and CEO," said Claude H. Nash, Ph.D., Chairman of Accera's Board of Directors.  "As Accera continues expanding its commercialization efforts for Axona® and initiates clinical trials with AC-1204, Dr. Werner's leadership will maximize Accera's development of therapeutic alternatives for Alzheimer's disease."

Based in part on available clinical data associated with Axona/AC-1202, Accera will forego conducting the traditional phase 1 dose-escalation trial of AC-1204 and proceed directl
'/>"/>

SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
2. Quark Pharmaceuticals Appoints New Chief Medical Officer
3. West Pharmaceutical Services, Inc. Appoints New Director
4. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
9. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
10. NovaRx Appoints Industry Veteran as President and COO
11. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Tenn. , May 23, 2013  TeamHealth ... 24-hour nurse triage and nurse advice lines, announces ... committee, comprising physician, nursing and administrative leaders, provides ... safe, quality and cost-effective services for hospital clients, ... our national healthcare system evolves, it,s imperative to ...
(Date:5/23/2013)... 23, 2013 Anthem Blue Cross patients with ... required them to obtain their medications by mail order ... Whatley Kallas LLC.  The lawsuit, filed ... Blue Cross,s mandatory mail order program announced late last ... privacy. "This settlement brings to a close ...
(Date:5/23/2013)... May 23, 2013  Spring Bank Pharmaceuticals, Inc., a ... viral infections, today announced that it has initiated dosing ... investigational, once daily, oral therapy for the treatment of ... patients and is designed to assess both the safety ... a first-in-class drug for the treatment of chronic HCV ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... ATLANTA, Jan. 26, 2011 The seasonal flu can be ... Centers for Disease Control and Prevention (CDC) recently recommended that ... for seniors (adults 65 and older). As people ... As a result, older adults are at greater risk of ...
... N.C., Jan. 26, 2011 MedCath Corporation (Nasdaq: ... closes on February 9, 2011 to announce results from its ... MedCath has elected not to host a conference call to ... Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused ...
Cached Medicine Technology:Blue Cross and Blue Shield of Georgia Urges Seniors to Get Flu and Pneumonia Vaccines 2Blue Cross and Blue Shield of Georgia Urges Seniors to Get Flu and Pneumonia Vaccines 3Blue Cross and Blue Shield of Georgia Urges Seniors to Get Flu and Pneumonia Vaccines 4
(Date:5/25/2013)... Communities of Distinction TV announces May air ... media market in the United States with almost three million ... Texas and a major convention city. Ft. Worth is known ... is home to many major museums. Both cities offer a ... arts. Residents and locals will be able to watch the ...
(Date:5/25/2013)... SATURDAY, May 25 (HealthDay News) -- Many viruses and ... rabies and leptospirosis -- a bacteria-borne illness than can ... lurking at dog parks, according to a veterinarian. ... water and even the air, said Dr. Susan Nelson, ... Health Center. "Many of these serious diseases can be ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Radius ... underground shelter company in the US and has ... structures for over 35 years. M.E. and President, ... Handbook of NBC Weapon Fundamentals and Shelter Engineering ... States’ bible on shelter engineering. McCarthy is considered ...
(Date:5/25/2013)... 25, 2013 Absolute Surgical Specialists, serving Sun ... the NALA’s businesses throughout the country participating in Shop Local ... in the nationwide event as he understands what military families ... the Army. He said, “I wanted to give something back, ... but I live here too.” , Shop Local for a ...
(Date:5/25/2013)... May 25, 2013 The latest ... from irritable bowel syndrome (IBS) to bloating, constipation, ... the most long-lasting, embarrassing, frustrating and difficult health ... for digestive health have provided a cure ... many factors contributing to digestive health issues, a ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... has enough capacity for typical season; experts less sure about ... current swine flu outbreak is raising critical questions about the ... logistics of getting it to the people who need it. ... into this fall,s production of seasonal influenza vaccine, experts say. ...
... war, blast injuries have become the signature injuries. These ... cause damage to the visual system and the visual processing ... wrong with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, ... LAKE, N.Y., May 18 The journey home is a ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... Preliminary results from the first-of-its-kind Clinical Evaluation and ... at the Society of Gastroenterology Nurses and Associates, Inc. ... The study indicated that while there are written endoscope ... in the study, significant variation in manual reprocessing takes ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... from Alcon and Initial Payments from New Galderma ... Calif., May 18 NovaBay Pharmaceuticals, Inc. (NYSE ... company developing first-in-class anti-infective products for the treatment ... without causing resistance, reported today its financial results ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9
... The CARDIA PDA Closure Device has been ... Patent Ductus Arteriosus. Introduced through standard venous ... and reliable method for the percutaneous closure ... from 2mm-10mm within the ductus.,An integral locking ...
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Medicine Products: